The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Florian M. E. Wagenlehner

Department of Urology

Pediatric Urology and Andrology





Name/email consistency: high



  • Department of Urology, Pediatric Urology and Andrology, Justus-Liebig-University, Giessen, Germany. 2007 - 2013
  • Department of Urology, University Giessen, Giessen, Germany. 2003 - 2012
  • Institute for Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany. 2003
  • Department of Medical Microbiology, Aberdeen Royal Infirmary, Aberdeen, UK. 2002
  • Urologic Clinic, Hospital St. Elisabeth, Teaching Hospital of the Technical University Munich, St. Elisabeth-Str. 23, Germany. 2000


  1. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Wagenlehner, F.M., van Till, J.W., Magri, V., Perletti, G., Houbiers, J.G., Weidner, W., Nickel, J.C. Eur. Urol. (2013) [Pubmed]
  2. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Wagenlehner, F.M., van Oostrum, E., Tenke, P., Tandogdu, Z., Çek, M., Grabe, M., Wullt, B., Pickard, R., Naber, K.G., Pilatz, A., Weidner, W., Bjerklund-Johansen, T.E. Eur. Urol. (2013) [Pubmed]
  3. Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. Wagenlehner, F.M., Cek, M., Naber, K.G., Kiyota, H., Bjerklund-Johansen, T.E. World. J. Urol (2012) [Pubmed]
  4. Urodynamic impact of acute urinary retention in patients with benign prostatic hyperplasia: a 2-year follow-up after transurethral resection of the prostate. Wagenlehner, F.M., Bescherer, K., Wagenlehner, C., Zellner, M., Weidner, W., Naber, K.G. Urol. Int. (2011) [Pubmed]
  5. Surgical reconstruction of pelvic floor descent: anatomic and functional aspects. Wagenlehner, F.M., Bschleipfer, T., Liedl, B., Gunnemann, A., Petros, P., Weidner, W. Urol. Int. (2010) [Pubmed]
  6. Urinary bactericidal activity of Doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. Wagenlehner, F.M., Wagenlehner, C., Redman, R., Weidner, W., Naber, K.G. Antimicrob. Agents Chemother. (2009) [Pubmed]
  7. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Wagenlehner, F.M., Schneider, H., Ludwig, M., Schnitker, J., Brähler, E., Weidner, W. Eur. Urol. (2009) [Pubmed]
  8. Prostatitis: no benefit of alpha-blockers for chronic prostatitis. Wagenlehner, F.M., Weidner, W. Nat. Rev. Urol (2009) [Pubmed]
  9. An update on uncomplicated urinary tract infections in women. Wagenlehner, F.M., Weidner, W., Naber, K.G. Curr. Opin. Urol (2009) [Pubmed]
  10. Prostatitis and male pelvic pain syndrome: diagnosis and treatment. Wagenlehner, F.M., Naber, K.G., Bschleipfer, T., Brähler, E., Weidner, W. Dtsch. Arztebl. Int (2009) [Pubmed]
  11. Spectrum and antibiotic resistance of uropathogens from hospitalised patients with urinary tract infections: 1994-2005. Wagenlehner, F.M., Niemetz, A.H., Weidner, W., Naber, K.G. Int. J. Antimicrob. Agents (2008) [Pubmed]
  12. Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. Wagenlehner, F.M., Kees, F., Weidner, W., Wagenlehner, C., Naber, K.G. Int. J. Antimicrob. Agents (2008) [Pubmed]
  13. Antibiotics in urology: new essentials. Wagenlehner, F.M., Weidner, W., Naber, K.G. Urol. Clin. North Am. (2008) [Pubmed]
  14. Chronic bacterial prostatitis (NIH type II): diagnosis, therapy and influence on the fertility status. Wagenlehner, F.M., Diemer, T., Naber, K.G., Weidner, W. Andrologia (2008) [Pubmed]
  15. Anti-infective treatment of bacterial urinary tract infections. Wagenlehner, F.M., Pilatz, A., Naber, K.G., Perletti, G., Wagenlehner, C.M., Weidner, W. Curr. Med. Chem. (2008) [Pubmed]
  16. Current anti-infective treatment of bacterial urinary tract infections. Wagenlehner, F.M., Wagenlehner, C., Naber, K.G., Weidner, W. Mini. Rev. Med. Chem (2008) [Pubmed]
  17. Therapeutic challenges of urosepsis. Wagenlehner, F.M., Pilatz, A., Naber, K.G., Weidner, W. Eur. J. Clin. Invest. (2008) [Pubmed]
  18. Management of a large healthcare-associated outbreak of Panton-Valentine leucocidin-positive meticillin-resistant Staphylococcus aureus in Germany. Wagenlehner, F.M., Naber, K.G., Bambl, E., Raab, U., Wagenlehner, C., Kahlau, D., Höller, C., Witte, W., Weidner, W., Lehn, N., Harbarth, S., Linde, H.J. J. Hosp. Infect. (2007) [Pubmed]
  19. Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis. Wagenlehner, F.M., Weidner, W., Naber, K.G. Clin. Pharmacokinet (2007) [Pubmed]
  20. The role of inflammation and infection in the pathogenesis of prostate carcinoma. Wagenlehner, F.M., Elkahwaji, J.E., Algaba, F., Bjerklund-Johansen, T., Naber, K.G., Hartung, R., Weidner, W. BJU Int. (2007) [Pubmed]
  21. Therapy for prostatitis, with emphasis on bacterial prostatitis. Wagenlehner, F.M., Weidner, W., Naber, K.G. Expert. Opin. Pharmacother (2007) [Pubmed]
  22. Optimal management of urosepsis from the urological perspective. Wagenlehner, F.M., Weidner, W., Naber, K.G. Int. J. Antimicrob. Agents (2007) [Pubmed]
  23. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Wagenlehner, F.M., Kinzig-Schippers, M., Tischmeyer, U., Wagenlehner, C., Sörgel, F., Dalhoff, A., Naber, K.G. Int. J. Antimicrob. Agents (2006) [Pubmed]
  24. Treatment of bacterial urinary tract infections: presence and future. Wagenlehner, F.M., Naber, K.G. Eur. Urol. (2006) [Pubmed]
  25. Chlamydial infections in urology. Wagenlehner, F.M., Weidner, W., Naber, K.G. World. J. Urol (2006) [Pubmed]
  26. Uraemia, psychosis, young patient: an uncommon link. Urinary tract and miliary tuberculosis. Wagenlehner, F.M., Piccoli, G.B., Naber, K.G. Nephrol. Dial. Transplant. (2006) [Pubmed]
  27. Chlamydial infections and prostatitis in men. Wagenlehner, F.M., Naber, K.G., Weidner, W. BJU Int. (2006) [Pubmed]
  28. Incidence of nosocomial urinary tract infections on a surgical intensive care unit and implications for management. Wagenlehner, F.M., Loibl, E., Vogel, H., Naber, K.G. Int. J. Antimicrob. Agents (2006) [Pubmed]
  29. Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Wagenlehner, F.M., Kinzig-Schippers, M., Tischmeyer, U., Wagenlehner, C., Sörgel, F., Naber, K.G. Antimicrob. Agents Chemother. (2006) [Pubmed]
  30. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Wagenlehner, F.M., Kinzig-Schippers, M., Sörgel, F., Weidner, W., Naber, K.G. Int. J. Antimicrob. Agents (2006) [Pubmed]
  31. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate. Wagenlehner, F.M., Lunz, J.C., Kees, F., Wieland, W., Naber, K.G. J. Chemother (2006) [Pubmed]
  32. Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/sulfamethoxazole versus a control group in patients undergoing TUR of the prostate. Wagenlehner, F.M., Wagenlehner, C., Schinzel, S., Naber, K.G. Eur. Urol. (2005) [Pubmed]
  33. Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations. Wagenlehner, F.M., Weidner, W., Naber, K.G. J. Hosp. Infect. (2005) [Pubmed]
  34. Emerging drugs for bacterial urinary tract infections. Wagenlehner, F.M., Weidner, W., Naber, K.G. Expert. Opin. Emerg. Drugs (2005) [Pubmed]
  35. The role of antibiotics in chronic bacterial prostatitis. Wagenlehner, F.M., Weidner, W., Sörgel, F., Naber, K.G. Int. J. Antimicrob. Agents (2005) [Pubmed]
  36. Asymptomatic bacteriuria in elderly patients: significance and implications for treatment. Wagenlehner, F.M., Naber, K.G., Weidner, W. Drugs. Aging (2005) [Pubmed]
  37. Emergence of antibiotic resistance and prudent use of antibiotic therapy in nosocomially acquired urinary tract infections. Wagenlehner, F.M., Naber, K.G. Int. J. Antimicrob. Agents (2004) [Pubmed]
  38. Antibiotic treatment for urinary tract infections: pharmacokinetic/pharmacodynamic principles. Wagenlehner, F.M., Naber, K.G. Expert. Rev. Anti. Infect. Ther (2004) [Pubmed]
  39. Prostatitis: the role of antibiotic treatment. Wagenlehner, F.M., Naber, K.G. World. J. Urol (2003) [Pubmed]
  40. Clinically significant borderline resistance of sequential clinical isolates of Klebsiella pneumoniae. Wagenlehner, F.M., Heisig, P., Irtenkauf, C., Notka, F., Decker, J., Lehn, N., Linde, H. Int. J. Antimicrob. Agents (2003) [Pubmed]
  41. Abdominal actinomycosis. Wagenlehner, F.M., Mohren, B., Naber, K.G., Männl, H.F. Clin. Microbiol. Infect. (2003) [Pubmed]
  42. Antimicrobial treatment of prostatitis. Wagenlehner, F.M., Naber, K.G. Expert. Rev. Anti. Infect. Ther (2003) [Pubmed]
  43. Molecular epidemiology and antibiotic resistance of Enterobacter spp. from three distinct populations in Grampian, UK. Wagenlehner, F.M., MacKenzie, F.M., Forbes, K.J., Gould, I.M. Int. J. Antimicrob. Agents (2002) [Pubmed]
  44. Hospital-acquired urinary tract infections. Wagenlehner, F.M., Naber, K.G. J. Hosp. Infect. (2000) [Pubmed]
WikiGenes - Universities